Brokerages Set Agenus Inc. (NASDAQ:AGEN) Target Price at $8.75

Agenus Inc. (NASDAQ:AGEN) has been assigned an average recommendation of “Hold” from the six brokerages that are currently covering the company, Marketbeat reports. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.75.

A number of equities research analysts have weighed in on the stock. Robert W. Baird decreased their price target on shares of Agenus from $6.00 to $3.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 12th. StockNews.com upgraded Agenus from a “sell” rating to a “hold” rating in a research report on Friday, March 21st. Finally, HC Wainwright reissued a “neutral” rating on shares of Agenus in a research note on Tuesday, March 18th.

Agenus Stock Down 3.6 %

AGEN opened at $1.60 on Wednesday. The stock’s 50 day moving average price is $2.85 and its two-hundred day moving average price is $3.56. The firm has a market capitalization of $40.49 million, a P/E ratio of -0.14 and a beta of 1.23. Agenus has a 12-month low of $1.55 and a 12-month high of $19.69.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.36) by $0.32. The company had revenue of $26.84 million during the quarter, compared to the consensus estimate of $30.09 million. As a group, analysts anticipate that Agenus will post -12.55 earnings per share for the current year.

Hedge Funds Weigh In On Agenus

A number of large investors have recently bought and sold shares of the company. Corton Capital Inc. bought a new stake in shares of Agenus during the 4th quarter worth approximately $36,000. Virtu Financial LLC bought a new position in Agenus in the 4th quarter valued at about $51,000. Apollon Wealth Management LLC bought a new position in shares of Agenus during the fourth quarter worth approximately $55,000. EP Wealth Advisors LLC bought a new position in Agenus during the 3rd quarter worth $55,000. Finally, Bank of Montreal Can acquired a new stake in Agenus in the 4th quarter worth about $69,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.